FDA Awareness Letters Have Impact, Allergan Counsel Says
An Allergan Inc. attorney on Friday told a U.S. Food and Drug Administration panel that the agency's awareness letters alerting medical providers of the possible use of counterfeit or unapproved pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article